MOXIFLOXACIN HYDROCHLORIDE | N205572 | FRESENIUS KABI USA LLC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 → 2027-02 | |
| Phase 3 | Active | University of California, San Francisco | 60 | 2024-07-01 → 2027-02-28 | |
| N/A | Active | Turku University Hospital | 552 | 2017-04-03 → 2029-04-01 | |
| Phase 1 | Active | Boehringer Ingelheim | 45 | 2026-04-22 → 2026-08-21 | |
| Phase 2 | Not Yet Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 → 2029-10-22 | |
| Phase 2/3 | Not Yet Recruiting | Jason Ahee, M.D. | 60,000 | 2026-06-01 → 2031-10 | |
| Phase 1 | Not Yet Recruiting | Boehringer Ingelheim | 56 | 2026-08-17 → 2026-12-30 | |
| N/A | Not Yet Recruiting | The First Affiliated Hospital of Shihezi University | 350 | 2026-09-01 → 2027-12 | |
| Phase 3 | Recruiting | UMC Utrecht | 20,000 | 2016-04-11 → 2028-02 | |
| Phase 2/3 | Recruiting | The University of Queensland | 300 | 2020-03-02 → 2030-06-30 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
17 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 30, 2020 | SUPPL -5 | View Letter (PDF) |
| May 7, 2019 | SUPPL -6 | View Letter (PDF) |
| Oct 23, 2018 | SUPPL -4 | View Letter (PDF) |
| Jul 26, 2016 | SUPPL -2 | View Letter (PDF) |
| Apr 8, 2015 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.